The Trastuzumab Biosimilars Global Market Report 2021-31 by The Business Research Company describes and explains the global trastuzumab biosimilars market and covers 2016 to 2021, termed the historic period, and 2022 to 2026, termed the forecast period, along with further forecasts for the period 2026-2031. The report evaluates the market across each region and for the major economies within each region.
The Trastuzumab Biosimilars Global Market Report 2022 covers trastuzumab biosimilars market drivers, trastuzumab biosimilars market trends, trastuzumab biosimilars market segments, trastuzumab biosimilars market growth rate, trastuzumab biosimilars market major players, and trastuzumab biosimilars market size.
View Complete Report:
https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report
The trastuzumab biosimilars market report provides in-depth analysis of the impact of COVID-19 on the global trastuzumab biosimilars industry along with revised market numbers due to the effects of the coronavirus and the expected trastuzumab biosimilars market growth numbers for 2022-2031.
The global trastuzumab biosimilars market size is expected to grow from $2.08 billion in 2021 to $2.64 billion in 2022 at a compound annual growth rate (CAGR) of 27.1%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The trastuzumab biosimilar market share is expected to reach $6.90 billion in 2026 at a CAGR of 27.1%.
Request Report Sample Now:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp
Trastuzumab Biosimilars Global Market Report 2022 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market. The chapter also covers markets which have been positively affected by the pandemic.
TBRC’s report covers the trastuzumab biosimilars market segments-
1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Others
2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Others
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy
Top 5 Major Key Players Are:
Amgen Inc
Pfizer Inc
Samsung Bioepis
Merck & Co
Biocon Limited
About The Business Research Company:
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology. It has offices in the UK, the US and India and a network of trained researchers in 20+ countries globally.
Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Find us on
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany/
Blog: http://blog.tbrc.info/
No comments:
Post a Comment